The other pandemic
In lock step with the pandemics of obesity and type 2 diabetes, another, less talked about condition is on the rise: non-alcoholic fatty liver disease (NAFLD).
Between 70 and 80% of people with type 2 diabetes also have NAFLD. And having diabetes also increases the risk of NAFLD’s progression to other, more severe forms of liver disease.
The latest course from EASD e-Learning aims to bring NAFLD out of the shadows and into the spotlight. The first module was co-authored and presented by eminent diabetologist Professor Michael Roden, one of the co-ordinators of the recent set of guidelines on managing NAFLD published jointly by the European associations for the study of diabetes, obesity and the liver (EASD, EASO and EASL).
The module provides an introduction to this serious but treatable condition, covering its epidemiology, pathophysiology and the mechanisms that underly its relationship with diabetes. It sets out the diagnostic tools clinicians can use to identify the condition and examines the therapeutic options currently available to help prevent NAFLD and its progression in people with diabetes.